BioSpace News Archive

Company to host investor call Monday, November 16th at 8:30 a.m. Eastern regarding third quarter 2020 financials & business updates

Vaxart, Inc., a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, announced that it will host a Key Opinion Leader panel for investors entitled “An Oral Tablet Vaccine – A Potential Global Solution to COVID-19 and Norovirus?” on Thursday, November 19, 2020 at 12pm Eastern Time.

Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO (Contract Commercial Organization), will host an Analyst and Investor Event on Tuesday, December 8, 2020, from 9:00 a.m. to approximately 11:30 a.m. EST.

Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan” or the “Company”) today reported financial results for the third quarter ended September 30, 2020 and provided an update on its business.

Acquisition Expands Medtronic’s Artificial Intelligence and Data Capabilities, Becoming the First Company to Offer an Integrated Spine Solution Including AI-Driven Surgical Planning, Personalized Spinal Implants and Robotic Assisted Surgery

Up to 55% of migraine patients do not have sufficient relief with currently available treatments.2 NURTEC™ ODT (rimegepant) can work quickly, returning patients to normal function in as little as one hour.

Intralink-Spine, Inc. announces that clinical sites in Australia are once again adding data supporting the safety and efficacy of their novel, injectable, nano-tethering device for the treatment of spinal disc degeneration and chronic low back pain.

DarwinAI, the explainable artificial intelligence (XAI) company, and Red Hat, the world’s leading provider of open source solutions, today announced a collaboration to accelerate the deployment of COVID-Net—a suite of deep neural networks for COVID-19 detection and risk stratification via chest radiography—to hospitals and other healthcare facilities.

Amylyx Pharmaceuticals, Inc., a pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and other neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to AMX0035 for the treatment of Wolfram syndrome. “There is a critical unmet need for people living with Wolfram syndrome, a r

OmniVision Technologies, Inc., a leading developer of advanced digital imaging solutions, and Almalence Inc., one of the world’s leaders in computational imaging, today announced at CompaMed a joint solution that eliminates the conflict between camera size and resolution found in current medical imaging solutions.